ADC Therapeutics SA Cash and Restricted Cash
ADC Therapeutics SA (ADCT) had Cash and Restricted Cash of $219.11 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $219.11M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $231.01M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $261.34M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $234.74M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $219.11M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $231.01M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $261.34M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $234.74M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $264.56M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $194.70M 10-Q · filed 2026-05-04 |
| 2024-12-31 | $250.87M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $274.27M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $300.12M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $234.28M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $278.60M 10-K · filed 2026-03-10 |
| 2023-09-30 | $310.41M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $347.51M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $310.55M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $326.44M 10-K · filed 2025-03-27 |
| 2021-12-31 | $466.54M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |